Literature DB >> 28830734

Post-Translational Peptide Splicing and T Cell Responses.

Michele Mishto1, Juliane Liepe2.   

Abstract

CD8+ T cell specificity depends on the recognition of MHC class I-epitope complexes at the cell surface. These epitopes are mainly produced via degradation of proteins by the proteasome, generating fragments of the original sequence. However, it is now clear that proteasomes can produce a significant portion of epitopes by reshuffling the antigen sequence, thus expanding the potential antigenic repertoire. MHC class I-restricted spliced epitopes have been described in tumors and infections, suggesting an unpredicted relevance of these peculiar peptides. We review current knowledge about proteasome-catalyzed peptide splicing (PCPS), the emerging rules governing this process, and the potential implications for our understanding and therapeutic use of CD8+ T cells, as well as mechanisms generating other non-canonical antigenic epitopes targeted by the T cell response.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28830734     DOI: 10.1016/j.it.2017.07.011

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  29 in total

Review 1.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

2.  Proteolytic dynamics of human 20S thymoproteasome.

Authors:  Ulrike Kuckelkorn; Sabine Stübler; Kathrin Textoris-Taube; Christiane Kilian; Agathe Niewienda; Petra Henklein; Katharina Janek; Michael P H Stumpf; Michele Mishto; Juliane Liepe
Journal:  J Biol Chem       Date:  2019-03-26       Impact factor: 5.157

3.  The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases.

Authors:  Juan Antonio Vizcaíno; Peter Kubiniok; Kevin A Kovalchik; Qing Ma; Jérôme D Duquette; Ian Mongrain; Eric W Deutsch; Bjoern Peters; Alessandro Sette; Isabelle Sirois; Etienne Caron
Journal:  Mol Cell Proteomics       Date:  2019-11-19       Impact factor: 5.911

4.  A Novel Proteogenomic Integration Strategy Expands the Breadth of Neo-Epitope Sources.

Authors:  Haitao Xiang; Le Zhang; Fanyu Bu; Xiangyu Guan; Lei Chen; Haibo Zhang; Yuntong Zhao; Huanyi Chen; Weicong Zhang; Yijian Li; Leo Jingyu Lee; Zhanlong Mei; Yuan Rao; Ying Gu; Yong Hou; Feng Mu; Xuan Dong
Journal:  Cancers (Basel)       Date:  2022-06-19       Impact factor: 6.575

5.  Global Identification of Post-Translationally Spliced Peptides with Neo-Fusion.

Authors:  Zach Rolfs; Stefan K Solntsev; Michael R Shortreed; Brian L Frey; Lloyd M Smith
Journal:  J Proteome Res       Date:  2018-10-31       Impact factor: 4.466

Review 6.  Hidden in Plain View: Discovery of Chimeric Diabetogenic CD4 T Cell Neo-Epitopes.

Authors:  Brendan K Reed; John W Kappler
Journal:  Front Immunol       Date:  2021-04-27       Impact factor: 7.561

7.  Database search engines and target database features impinge upon the identification of post-translationally cis-spliced peptides in HLA class I immunopeptidomes.

Authors:  Michele Mishto; Yehor Horokhovskyi; John A Cormican; Xiaoping Yang; Steven Lynham; Henning Urlaub; Juliane Liepe
Journal:  Proteomics       Date:  2022-03-03       Impact factor: 5.393

8.  Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.

Authors:  Pengcheng Wei; Kimberly R Jordan; Jonathan D Buhrman; Jun Lei; Hexiang Deng; Philippa Marrack; Shaodong Dai; John W Kappler; Jill E Slansky; Lei Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

9.  Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides.

Authors:  Alessia Melacarne; Valentina Ferrari; Luca Tiraboschi; Michele Mishto; Juliane Liepe; Marina Aralla; Laura Marconato; Michela Lizier; Chiara Pozzi; Offer Zeira; Giuseppe Penna; Maria Rescigno
Journal:  Cell Rep       Date:  2021-07-06       Impact factor: 9.423

10.  Response: Commentary: An In Silico-In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients.

Authors:  Michele Mishto; Guillermo Rodriguez-Hernandez; Jacques Neefjes; Henning Urlaub; Juliane Liepe
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.